Search Results - "Ruijs, Titia Q."

Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double‐blind placebo‐controlled cross‐over study by Ruijs, Titia Q., Koopmans, Ingrid W., Kam, Marieke L., Tannemaat, Martijn R., Groeneveld, Geert Jan, Heuberger, Jules A. A. C.

“…Measuring muscle velocity recovery cycles (MVRCs) is a method to obtain information on muscle cell excitability, independent of neuromuscular transmission. The…”
Get full text

Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation by O’Donnell, Patricio, Dijkstra, Francis M., Damar, Ugur, Quanhong, Lei, de Goede, Annika A., Xu, Lin, Pascual-Leone, Andres, Buhl, Derek L., Zuiker, Rob, Ruijs, Titia Q., Heuberger, Jules A. A. C., MacMullin, Paul, Lubell, Martin, Asgharnejad, Mahnaz, Murthy, Venkatesha, Rotenberg, Alexander, Jacobs, Gabriel E., Rosen, Laura

“…TAK-653 is a novel α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-positive allosteric modulator being developed as a potential…”
Get full text

Effects of Mexiletine and Lacosamide on Nerve Excitability in Healthy Subjects: A Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study by Ruijs, Titia Q., Koopmans, Ingrid W., Kam, Marieke L., Esdonk, Michiel J., Koltzenburg, Martin, Groeneveld, Geert Jan, Heuberger, Jules A.A.C.

“…Selective voltage‐gated sodium channel blockers are of growing interest as treatment for pain. For drug development of such compounds, it would be critical to…”
Get full text

Transcranial magnetic stimulation as biomarker of excitability in drug development: A randomized, double‐blind, placebo‐controlled, cross‐over study by Ruijs, Titia Q., Heuberger, Jules A. A. C., Goede, Annika A., Ziagkos, Dimitrios, Otto, Marije E., Doll, Robert J., Putten, Michel J. A. M., Groeneveld, Geert Jan

“…Aims The purpose of this study was to investigate pharmacodynamic effects of drugs targeting cortical excitability using transcranial magnetic stimulation…”
Get full text

The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis by Skov, Martin, Ruijs, Titia Q, Grønnebæk, Thomas S, Skals, Marianne, Riisager, Anders, Winther, Jeppe Blichfeldt, Dybdahl, Kamilla Løhde Tordrup, Findsen, Anders, Morgen, Jeanette J, Huus, Nete, Broch-Lips, Martin, Nielsen, Ole B, de Cuba, Catherine M K E, Heuberger, Jules A A C, de Kam, Marieke L, Tannemaat, Martijn, Verschuuren, Jan J G M, Knutsen, Lars J S, Kelly, Nicholas M, Jensen, Klaus G, Arnold, William D, Burghes, Arthur H, Olesen, Claus, Bold, Jane, Petersen, Thomas K, Quiroz, Jorge A, Hutchison, John, Chin, Eva R, Groeneveld, Geert J, Pedersen, Thomas H

“…Myasthenia gravis (MG) is a neuromuscular disease that results in compromised transmission of electrical signals at the neuromuscular junction (NMJ) from motor…”
Get more information